Positive results from second pivotal phase 3 study of brodalumab in patients with moderate-to-severe plaque psoriasis announced
Amgen and AstraZeneca has announced that AMAGINE-3™, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints (more…)
Read More
